CIPROFLOXACIN- ciprofloxacin tablet, film coated United States - English - NLM (National Library of Medicine)

ciprofloxacin- ciprofloxacin tablet, film coated

a-s medication solutions - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 250 mg - ciprofloxacin tablets are indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin­ susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin tablets are indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin tablets are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin tablets are indicated in adult patients for treatment of infectious diarrhea caused by escherichia coli ( enterotoxigenic isol

CIPROFLOXACIN- ciprofloxacin tablet, film coated United States - English - NLM (National Library of Medicine)

ciprofloxacin- ciprofloxacin tablet, film coated

a-s medication solutions - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin tablets, usp are indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin­ susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin tablets, usp are indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin tablets, usp are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin tablets, usp are indicated in adult patients for treatment of infectious diarrhea caused by escherichia coli (

CIPROFLOXACIN - ciprofloxacin tablet United States - English - NLM (National Library of Medicine)

ciprofloxacin - ciprofloxacin tablet

a-s medication solutions - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , proteus mirabilis , proteus vulgaris , providencia stuartii , morganella morganii , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus aureus , methicillin-susceptible staphylococcus epidermidis , or streptococcus pyogenes . ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by escherichia coli (enterotoxigenic isolates), campylobacter jejuni

CIPROFLOXACIN- ciprofloxacin hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

ciprofloxacin- ciprofloxacin hydrochloride tablet, film coated

remedyrepack inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by escherichia coli (enterotoxigenic isolates), campylobacter jejuni, shigella

CIPROFLOXACIN- ciprofloxacin hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

ciprofloxacin- ciprofloxacin hydrochloride tablet, film coated

quality care products, llc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin is indicated in adult patients for treatment of i

CIPROFLOXACIN- ciprofloxacin hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

ciprofloxacin- ciprofloxacin hydrochloride tablet, film coated

liberty pharmaceuticals, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin is indicated in adult patients for treatment of i

International Biolux New Technology Micron AP High Strength Self Polishing Antifouling Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international biolux new technology micron ap high strength self polishing antifouling

akzo nobel pty limited - zineb; zineb; copper present as cuprous oxide; copper present as cuprous oxide; liquid hydrocarbon; liquid hydrocarbon; liquid hydrocarbon; liquid hydrocarbon - paint - zineb carbamate-dithiocarbamate active 90.0 g/l; zineb carbamate-dithiocarbamate active 88.0 g/l; copper present as cuprous oxide mineral-copper active 710.0 g/l; copper present as cuprous oxide mineral-copper active 694.0 g/l; liquid hydrocarbon solvent other 357.0 g/l; liquid hydrocarbon solvent other 364.0 g/l; liquid hydrocarbon solvent other 365.0 g/l; liquid hydrocarbon solvent other 374.0 g/l - antifouling

CIPROFLOXACIN tablet United States - English - NLM (National Library of Medicine)

ciprofloxacin tablet

drug ocean llc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , proteus mirabilis , proteus vulgaris , providencia stuartii , morganella morganii , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus aureus , methicillin-susceptible staphylococcus epidermidis , or streptococcus pyogenes . ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by escherichia coli (enterotoxigenic isolates), campylobacter jejuni , shigella boydii† , shigella dysenteriae , shigella flexneri or shigella sonnei† when antibacterial therapy is indicated. †although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by salmonella typhi . the efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to neisseria gonorrhoeae [see warnings and precautions (5.17)]. ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication. 1 supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of october 2001 [see clinical studies (14.2)]. ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to yersinia pestis (y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. therefore this indication is based on an efficacy study conducted in animals only [ see clinical studies (14.3)] . ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis . ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , proteus mirabilis , pseudomonas aeruginosa , haemophilus influenzae , haemophilus parainfluenzae , or streptococcus pneumoniae . ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to streptococcus pneumoniae . ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis (aecb) caused by moraxella catarrhalis . because fluoroquinolones, including ciprofloxacin, have been associated with serious adverse reactions [see warnings and precautions (5.1–5.16)] and for some patients aecb is self-limiting, reserve ciprofloxacin for treatment of aecb in patients who have no alternative treatment options. urinary tract infections in adults ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter koseri , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . acute uncomplicated cystitis ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by escherichia coli or staphylococcus saprophyticus . because fluoroquinolones, including ciprofloxacin, have been associated with serious adverse reactions [see warnings and precautions (5.1-5.16)] and for some patients acute uncomplicated cystitis is self-limiting, reserve ciprofloxacin tablets for treatment of acute uncomplicated cystitis in patients who have no alternative treatment options. complicated urinary tract infection and pyelonephritis in pediatric patients ciprofloxacin is indicated in pediatric patients aged one to 17 years of age for treatment of complicated urinary tract infections (cuti) and pyelonephritis due to escherichia coli [see use in specific populations (8.4)]. although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse reactions compared to controls, including reactions related to joints and/or surrounding tissues. ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see warnings and precautions (5.13), adverse reactions (6.1), use in specific populations (8.4) and nonclinical toxicology (13.2)]. ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by haemophilus influenzae , streptococcus pneumoniae , or moraxella catarrhalis . because fluoroquinolones, including ciprofloxacin, have been associated with serious adverse reactions [see warnings and precautions (5.1-5.16)] and for some patients acute sinusitis is self-limiting, reserve ciprofloxacin for treatment of acute sinusitis in patients who have no alternative treatment options. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs, ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. if anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. as with other drugs, some isolates of pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. ciprofloxacin tablet is contraindicated in persons with a history of hypersensitivity to ciprofloxacin, any member of the quinolone class of antibacterials, or any of the product components [see warnings and precautions (5.7)]. concomitant administration with tizanidine is contraindicated [see drug interactions (7)]. risk summary prolonged experience with ciprofloxacin in pregnant women over several decades, based on available published information from case reports, case control studies and observational studies on ciprofloxacin administered during pregnancy, have not identified any drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). oral administration of ciprofloxacin during organogenesis at doses up to 100 mg/kg to pregnant mice and rats, and up to 30 mg/kg to pregnant rabbits did not cause fetal malformations (see data). these doses were up to 0.3, 0.6, and 0.4 times the maximum recommended clinical oral dose in mice, rats, and rabbits, respectively, based on body surface area. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancieshave a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.  data human data while available studies cannot definitively establish the absence of risk, published data from prospective observational studies over several decades have not established an association with ciprofloxacin use during pregnancy and major birth defects, miscarriage, or adverse maternalor fetal outcomes. available studies have methodological limitations including small sample size and some of them are not specific for ciprofloxacin. a controlled prospective observational study followed 200 women exposed to fluoroquinolones (52.5% exposed to ciprofloxacin and68% first trimester exposures) during gestation. in utero exposure to fluoroquinolones during embryogenesis was not associated with increased risk of major malformations. the reported rates of major congenital malformations were 2.2% for the fluoroquinolone group and 2.6% forthe control group (background incidence of major malformations is 1–5%). rates of spontaneous abortions, prematurity and low birth weight did not differ between the groups and there were no clinically significant musculoskeletal dysfunctions up to one year of age in the ciprofloxacinexposed children. another prospective follow-up study reported on 549 pregnancies with fluoroquinolone exposure (93% first trimester exposures). there were 70 ciprofloxacin exposures, all within the first trimester. the malformation rates among live-born babies exposed to ciprofloxacin and to fluoroquinolones overall were both within background incidence ranges. no specific patterns of congenital abnormalities were found. the study did not reveal any clear adverse reactions due to in utero exposure to ciprofloxacin. no differences in the rates of prematurity, spontaneous abortions, or birth weight were seen in women exposed to ciprofloxacin during pregnancy. however, these small postmarketing epidemiology studies, of which most experience is from short term, first trimester exposure, are insufficient to evaluate the risk for less common defects or to permit reliable and definitive conclusions regarding the safety of ciprofloxacin in pregnant women and their developing fetuses.  animal data developmental toxicology studies have been performed with ciprofloxacin in rats, mice, and rabbits. in rats and mice, oral doses up to 100 mg/kg administered during organogenesis (gestation days, gd, 6-17) were not associated with adverse developmental outcomes, including embryofetal toxicity or malformations. in rats and mice, a 100 mg/kg dose is approximately 0.6 and 0.3 times the maximum daily human oral dose (1500 mg/day) based upon body surface area, respectively. in a series of rabbit developmental toxicology studies, does received oral or intravenous ciprofloxacin for one of the following 5 day periods: gd 6 to 10, gd 10 to 14, or gd 14 to 18, intended to cover the period of organogenesis. this was an attempt to mitigate the gastrointestinal intolerance observed in rabbits that receive antibacterials manifested by reduced maternal food consumption and weight loss, that can lead to embryofetal resorption or spontaneous abortion. an oral ciprofloxacin dose of 100 mg/kg (approximately 1.3 times the highest recommended clinical oral dose based on body surface area) caused excessive maternal toxicity confounding evaluation of the fetuses. a 30 mg/kg oral dose (approximately 0.4 times the highest recommended clinical oral dose) was associated with suppression of maternal and fetal body weight gain, but fetal malformations were not observed. intravenous administration of doses up to 20 mg/kg (approximately 0.3 times the highest recommended clinical oral dose based upon body surface area) to pregnant rabbits was not maternally toxic and neither embryofetal toxicity nor fetal malformations were observed. in peri-and post-natal studies, rats received ciprofloxacin doses up to 200 mg/kg/day (oral) or up to 30 mg/kg/day (subcutaneous) from gd 16 to 22 days postpartum. the 200 mg/kg dose is approximately 1.3-times the maximum recommended clinical oral dose based on body surfacearea. neither maternal toxicity nor adverse effects on growth and development of the pups were observed, including no sign of arthropathy on the rear leg joints of the pups. ciprofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most speciestested when administered directly [see warnings and precautions (5.13) and nonclinical toxicology 13.2]. risk summary published literature reports that ciprofloxacin is present in human milk following intravenous and oral administration. there is no information regarding effects of ciprofloxacin on milk production or the breastfed infant. because of the potential risk of serious adverse reactions in breastfed infants, including arthropathy shown in juvenile animal studies [see use in specific populations (8.4), (clinical considerations)], for most indications a lactating woman may consider pumping and discarding breast milk during treatment with ciprofloxacin and an additional two days (five half-lives) after the last dose. alternatively, advise a woman that breastfeeding is not recommended during treatment with ciprofloxacin and for an additional two days (five half-lives) after the last dose. however, for inhalation anthrax (post exposure), during an incident resulting in exposure to anthrax, the risk-benefit assessment of continuing breastfeeding while the mother (and potentially the infant) is (are) on ciprofloxacin may be acceptable [see dosage and administration (2.2), pediatric use (8.4), and clinical studies (14.2)]. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ciprofloxacin and any potential adverse effects on the breastfed child from ciprofloxacin or from the underlying maternal condition.  clinical considerations ciprofloxacin may cause intestinal flora alteration of the breastfeeding infant. advise a woman to monitor the breastfed infant for loose or bloody stools and candidiasis (thrush, diaper rash). although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse reactions compared to controls. quinolones, including ciprofloxacin, cause arthropathy (arthralgia, arthritis), in juvenile animals [see warnings and precautions (5.13) and nonclinical toxicology (13.2)] . complicated urinary tract infection and pyelonephritis ciprofloxacin is indicated for the treatment of cuti and pyelonephritis due to escherichia coli in pediatric patients 1 to 17 years of age . although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse reactions compared to the controls, including events related to joints and/or surrounding tissues [see adverse reactions (6.1) and clinical studies (14.1)]. inhalational anthrax (post-exposure) ciprofloxacin is indicated in pediatric patients from birth to 17 years of age, for inhalational anthrax (post-exposure). the risk-benefit assessment indicates that administration of ciprofloxacin to pediatric patients is appropriate [see dosage and administration (2.2) and clinical studies (14.2)]. plague ciprofloxacin is indicated in pediatric patients from birth to 17 years of age, for treatment of plague, including pneumonic and septicemic plague due to yersinia pestis (y. pestis) and prophylaxis for plague. efficacy studies of ciprofloxacin could not be conducted in humans with pneumonic plague for feasibility reasons. therefore, approval of this indication was based on an efficacy study conducted in animals. the risk-benefit assessment indicates that administration of ciprofloxacin to pediatric patients is appropriate [see indications and usage (1.8), dosage and administration (2.2) and clinical studies (14.3)]. geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as ciprofloxacin. this risk is further increased in patients receiving concomitant corticosteroid therapy. tendinitis or tendon rupture can involve the achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. caution should be used when prescribing ciprofloxacin to elderly patients especially those on corticosteroids. patients should be informed of this potential adverse reaction and advised to discontinue ciprofloxacin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur [see boxed warning, warnings and precautions (5.2), and adverse reactions (6.2)]. epidemiologic studies report an increased rate of aortic aneurysm and dissection within two months following use of fluoroquinolones, particularly in elderly patients [see warnings and precautions (5.9)]. in a retrospective analysis of 23 multiple-dose controlled clinical trials of ciprofloxacin encompassing over 3500 ciprofloxacin-treated patients, 25% of patients were greater than or equal to 65 years of age and 10% were greater than or equal to 75 years of age. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals on any drug therapy cannot be ruled out. ciprofloxacin is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. no alteration of dosage is necessary for patients greater than 65 years of age with normal renal function. however, since some older individuals experience reduced renal function by virtue of their advanced age, care should be taken in dose selection for elderly patients, and renal function monitoring may be useful in these patients [see dosage and administration (2.3) and clinical pharmacology (12.3)]. in general, elderly patients may be more susceptible to drug-associated effects on the qt interval. therefore, precaution should be taken when using ciprofloxacin with concomitant drugs that can result in prolongation of the qt interval (for example, class ia or class iii antiarrhythmics) or in patients with risk factors for torsade de pointes (for example, known qt prolongation, uncorrected hypokalemia) [see warnings and precautions (5.12)]. ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. these alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction [see  dosage and administration (2.3) and clinical pharmacology (12.3)]. in preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin pharmacokinetics have been observed. the pharmacokinetics of ciprofloxacin in patients with acute hepatic insufficiency, have not been studied. read this medication guide before you start taking ciprofloxacin tablets and each time you get a refill. there may be new information. this information does not take the place of talking to your healthcare provider about your medical condition or your treatment. what is the most important information i should know about ciprofloxacin tablets? ciprofloxacin tablets, a fluoroquinolone antibacterial medicine, can cause serious side effects. some of these serious side effects can happen at the same time and could result in death. if you get any of the following serious side effects while you take ciprofloxacin tablets, you should stop taking ciprofloxacin tablets immediately and get medical help right away. 1. tendon rupture or swelling of the tendon (tendinitis). - tendon problems can happen in people of all ages who take ciprofloxacin tablets. tendons are tough cords of tissue that connect muscles to bones. symptoms of tendon problems may include: pain swelling tears and swelling of the tendons including the back of the ankle (achilles), shoulder, hand, or other tendon sites. - pain - swelling - tears and swelling of the tendons including the back of the ankle (achilles), shoulder, hand, or other tendon sites. - the risk of getting tendon problems while you take ciprofloxacin tablets is higher if you: are over 60 years of age are taking steroids (corticosteroids) have had a kidney, heart or lung transplant - are over 60 years of age - are taking steroids (corticosteroids) - have had a kidney, heart or lung transplant - tendon problems can happen in people who do not have the above risk factors when they take ciprofloxacin tablets. - other reasons that can increase your risk of tendon problems can include: physical activity or exercise kidney failure tendon problems in the past, such as in people with rheumatoid arthritis (ra) - physical activity or exercise - kidney failure - tendon problems in the past, such as in people with rheumatoid arthritis (ra) - stop taking ciprofloxacin tablets immediately and get medical help right away at the first sign of tendon pain, swelling or inflammation. the most common area of pain and swelling is the achilles tendon at the back of your ankle. this can also happen with other tendons. - tendon rupture can happen while you are taking or after you have finished taking ciprofloxacin tablets. tendon ruptures can happen within hours or days of taking ciprofloxacin tablets and have happened up to several months after people have finished taking their fluoroquinolone. - stop taking ciprofloxacin tablets immediately and get medical help right away if you get any of the following signs or symptoms of a tendon rupture: - hear or feel a snap or pop in a tendon area bruising right after an injury in a tendon area unable to move the affected area or bear weight - hear or feel a snap or pop in a tendon area - bruising right after an injury in a tendon area - unable to move the affected area or bear weight the tendon problems may be permanent. 2. changes in sensation and possible nerve damage (peripheral neuropathy). damage to the nerves in arms, hands, legs, or feet can happen in people who take fluoroquinolones, including ciprofloxacin tablets. stop taking ciprofloxacin tablets immediately and talk to your healthcare provider right away if you get any of the following symptoms of peripheral neuropathy in your arms, hands, legs, or feet: - pain - burning - tingling - numbness - weakness ciprofloxacin tablets may need to be stopped to prevent permanent nerve damage. 3. central nervous system (cns) effects. seizures have been reported in people who take fluoroquinolone antibacterial medicines, including ciprofloxacin tablets. tell your healthcare provider if you have a history of seizures before you start taking ciprofloxacin tablets. cns side effects may happen as soon as after taking the first dose of ciprofloxacin. stop taking ciprofloxacin tablets immediately and talk to your healthcare provider right away if you get any of these side effects, or other changes in mood or behavior: - seizures - hear voices, see things, or sense things that are not there (hallucinations) - feel restless - tremors - feel anxious or nervous - confusion - depression - reduced awareness of surroundings - trouble sleeping - nightmares - feel lightheaded or dizzy - feel more suspicious (paranoia) - suicidal thoughts or acts - headaches that will not go away, with or without blurred vision - memory problems - false or strange thoughts or beliefs (delusions) the cns changes may be permanent 4. worsening of myasthenia gravis (a problem that causes muscle weakness). fluoroquinolones like ciprofloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. tell your healthcare provider if you have a history of myasthenia gravis before you start taking ciprofloxacin tablets. call your healthcare provider right away if you have any worsening muscle weakness or breathing problems. what are ciprofloxacin tablets? ciprofloxacin tablets are a fluoroquinolone antibacterial medicine used in adults age 18 years and older to treat certain infections caused by certain germs called bacteria. these bacterial infections include: - urinary tract infection - chronic prostate infection - lower respiratory tract infection - sinus infection - skin infection - bone and joint infection - nosocomial pneumonia - intra-abdominal infection, complicated - infectious diarrhea - typhoid (enteric) fever - cervical and urethral gonorrhea, uncomplicated - people with a low white blood cell count and a fever - inhalational anthrax - plague - studies of ciprofloxacin tablets for use in the treatment of plague and anthrax were done in animals only, because plague and anthrax could not be studied in people. - ciprofloxacin should not be used in patients with acute exacerbation of chronic bronchitis, acute uncomplicated cystitis, and sinus infections, if there are other treatment options available. - ciprofloxacin should not be used as the first choice of antibacterial medicine to treat lower respiratory tract infections cause by a certain type of bacterial called streptococcus pneumoniae . - ciprofloxacin is also used in children younger than 18 years of age to treat complicated urinary tract and kidney infections or who may have breathed in anthrax germs, have plague or have been exposed to plague germs. - children younger than 18 years of age have a higher chance of getting bone, joint, or tendon (musculoskeletal) problems such as pain or swelling while taking ciprofloxacin. ciprofloxacin should not be used as the first choice of antibacterial medicine in children under 18 years of age. who should not take ciprofloxacin tablets? do not take ciprofloxacin tablets if you: - have ever had a severe allergic reaction to an antibacterial medicine known as a fluoroquinolone, or are allergic to ciprofloxacin hydrochloride or any of the ingredients in ciprofloxacin tablets. see the end of this medication guide for a complete list of ingredients in ciprofloxacin tablets. - also take a medicine called tizanidine (zanaflex ® ). ask your healthcare provider if you are not sure. what should i tell my healthcare provider before taking ciprofloxacin tablets? before you take ciprofloxacin tablets, tell your healthcare provider if you: - have tendon problems; ciprofloxacin tablets should not be used in patients who have a history of tendon problems - have a disease that causes muscle weakness (myasthenia gravis); ciprofloxacin tablets should not be used in patients who have a known history of myasthenia gravis - have liver problems - have central nervous system problems (such as epilepsy) - have nerve problems; ciprofloxacin tablets should not be used in patients who have a history of a nerve problem called peripheral neuropathy - have or anyone in your family has an irregular heartbeat, especially a condition called "qt prolongation" - have low blood potassium (hypokalemia) or low magnesium (hypomagnesemia). - have or have had seizures - have kidney problems. you may need a lower dose of ciprofloxacin tablets if your kidneys do not work well. - have diabetes or problems with low blood sugar (hypoglycemia). - have joint problems including rheumatoid arthritis (ra) - have trouble swallowing pills - are pregnant or plan to become pregnant. it is not known if ciprofloxacin will harm your unborn baby. - are breastfeeding or plan to breastfeed. ciprofloxacin passes into your breast milk. - you should not breastfeed during treatment with ciprofloxacin tablets and for 2 days after taking your last dose of ciprofloxacin tablets and for 2 days after taking your last dose of ciprofloxacin tablets. - if you are taking ciprofloxacin tablets for inhalation anthrax, you and your healthcare provider should decide whether you can continue breastfeeding while taking ciprofloxacin tablets. tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. - ciprofloxacin tablets and other medicines can affect each other causing side effects. - especially tell your healthcare provider if you take: a steroid medicine an anti-psychotic medicine a tricyclic antidepressant a water pill (diuretic) theophylline (such as theo-24 ® , elixophyllin ® , theochron ® , uniphyl ® , theolair ® ) a medicine to control your heart rate or rhythm (antiarrhythmics) an oral anti-diabetes medicine phenytoin (fosphenytoin sodium ® , cerebyx ® , dilantin-125 ® , dilantin ® , extended phenytoin sodium ® , prompt phenytoin sodium ® , phenytek ® ) cyclosporine (gengraf ® , neoral ® , sandimmune ® , sangcya ® ). a blood thinner (such as warfarin, coumadin ® , jantoven ® ) methotrexate (trexall ® ) ropinirole (requip ® ) clozapine (clozaril ® , fazaclo ® odt ® ) a non-steroidal anti-inflammatory drug (nsaid). many common medicines for pain relief are nsaids. taking an nsaid while you take ciprofloxacin or other fluoroquinolones may increase your risk of central nervous system effects and seizures. sildenafil (viagra ® , revatio ® ) duloxetine products that contain caffeine probenecid (probalan ® , col-probenecid ® ) - a steroid medicine - an anti-psychotic medicine - a tricyclic antidepressant - a water pill (diuretic) - theophylline (such as theo-24 ® , elixophyllin ® , theochron ® , uniphyl ® , theolair ® ) - a medicine to control your heart rate or rhythm (antiarrhythmics) - an oral anti-diabetes medicine - phenytoin (fosphenytoin sodium ® , cerebyx ® , dilantin-125 ® , dilantin ® , extended phenytoin sodium ® , prompt phenytoin sodium ® , phenytek ® ) - cyclosporine (gengraf ® , neoral ® , sandimmune ® , sangcya ® ). - a blood thinner (such as warfarin, coumadin ® , jantoven ® ) - methotrexate (trexall ® ) - ropinirole (requip ® ) - clozapine (clozaril ® , fazaclo ® odt ® ) - a non-steroidal anti-inflammatory drug (nsaid). many common medicines for pain relief are nsaids. taking an nsaid while you take ciprofloxacin or other fluoroquinolones may increase your risk of central nervous system effects and seizures. - sildenafil (viagra ® , revatio ® ) - duloxetine - products that contain caffeine - probenecid (probalan ® , col-probenecid ® ) - certain medicines may keep ciprofloxacin tablets from working correctly. take ciprofloxacin tablets either 2 hours before or 6 hours after taking these medicines, vitamins, or supplements: an antacid, multivitamin, or other medicine or supplements that has magnesium, calcium, aluminum, iron, or zinc sucralfate (carafate ® ) didanosine (videx ® , videx ec ® ) - an antacid, multivitamin, or other medicine or supplements that has magnesium, calcium, aluminum, iron, or zinc - sucralfate (carafate ® ) - didanosine (videx ® , videx ec ® ) ask your healthcare provider for a list of these medicines if you are not sure. know the medicines you take. keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. how should i take ciprofloxacin tablets? - take ciprofloxacin tablets exactly as your healthcare provider tells you to take it. - your healthcare provider will tell you how much ciprofloxacin tablets to take and when to take it. - take ciprofloxacin tablets in the morning and evening at about the same time each day. swallow the tablet whole. do not split, crush or chew the tablet. tell your healthcare provider if you cannot swallow the tablet whole. - ciprofloxacin tablets can be taken with or without food. - if you miss a dose of ciprofloxacin tablets and it is:o 6 hours or more until your next scheduled dose, take your missed dose right away. then take the next dose at your regular time.o less than 6 hours until your next scheduled dose, do not take the missed dose. take the next dose at your regular time. - do not take 2 doses of ciprofloxacin tablets at one time to make up for a missed dose. if you are not sure about when to take ciprofloxacin tablets after a missed dose, ask your doctor or pharmacist. - ciprofloxacin tablets should not be taken with dairy products (like milk or yogurt) or calcium-fortified juices alone, but may be taken with a meal that contains these products. - drink plenty of fluids while taking ciprofloxacin tablets. - do not skip any doses of ciprofloxacin tablets, or stop taking it, even if you begin to feel better, until you finish your prescribed treatment unless: you have tendon problems. see " what is the most important information i should know about ciprofloxacin tablets?” you have nerve problems. see "what is the most important information i should know about ciprofloxacin tablets?" you have central nervous system problems. see "what is the most important information i should know about ciprofloxacin tablets?" you have a serious allergic reaction. see "what are the possible side effects of ciprofloxacin tablets?" your healthcare provider tells you to stop taking ciprofloxacin tablets. - you have tendon problems. see " what is the most important information i should know about ciprofloxacin tablets?” - you have nerve problems. see "what is the most important information i should know about ciprofloxacin tablets?" - you have central nervous system problems. see "what is the most important information i should know about ciprofloxacin tablets?" - you have a serious allergic reaction. see "what are the possible side effects of ciprofloxacin tablets?" - your healthcare provider tells you to stop taking ciprofloxacin tablets. taking all of your ciprofloxacin doses will help make sure that all of the bacteria are killed. taking all of your ciprofloxacin doses will help lower the chance that the bacteria will become resistant to ciprofloxacin. if you become resistant to ciprofloxacin, ciprofloxacin tablets and other antibacterial medicines may not work for you in the future. - if you take too much ciprofloxacin tablets, call your healthcare provider or get medical help right away. what should i avoid while taking ciprofloxacin tablets? - ciprofloxacin tablets can make you feel dizzy and lightheaded. do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how ciprofloxacin tablets affects you. - avoid sunlamps, tanning beds, and try to limit your time in the sun. ciprofloxacin tablets can make your skin sensitive to the sun (photosensitivity) and the light from sunlamps and tanning beds. you could get a severe sunburn, blisters or swelling of your skin. if you get any of these symptoms while you take ciprofloxacin tablets, call your healthcare provider right away. you should use a sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight. what are the possible side effects of ciprofloxacin tablets? ciprofloxacin tablets may cause serious side effects, including: - see, "what is the most important information i should know about ciprofloxacin tablets?" - serious allergic reactions. serious allergic reactions, including death, can happen in people taking fluoroquinolones, including ciprofloxacin tablets, even after only 1 dose. stop taking ciprofloxacin tablets and get emergency medical help right away if you get any of the following symptoms of a severe allergic reaction: hives trouble breathing or swallowing swelling of the lips, tongue, face throat tightness, hoarseness rapid heartbeat faint skin rash - hives - trouble breathing or swallowing - swelling of the lips, tongue, face - throat tightness, hoarseness - rapid heartbeat - faint - skin rash skin rash may happen in people taking ciprofloxacin tablets even after only 1 dose. stop taking ciprofloxacin tablets at the first sign of a skin rash and call your healthcare provider, skin rash may be a sign of a more serious reaction to ciprofloxacin. - liver damage (hepatotoxicity). hepatotoxicity can happen in people who take ciprofloxacin tablets. call your healthcare provider right away if you have unexplained symptoms such as: nausea or vomiting stomach pain fever weakness abdominal pain or tenderness itching unusual tiredness loss of appetite light colored bowel movements dark colored urine yellowing of your skin or the whites of your eyes - nausea or vomiting - stomach pain - fever - weakness - abdominal pain or tenderness - itching - unusual tiredness - loss of appetite - light colored bowel movements - dark colored urine - yellowing of your skin or the whites of your eyes stop taking ciprofloxacin tablets and tell your healthcare provider right away if you have yellowing of your skin or white part of your eyes, or if you have dark urine. these can be signs of a serious reaction to ciprofloxacin tablets (a liver problem). - aortic aneurysm and dissection. tell your healthcare provider if you have ever been told that you have an aortic aneurysm, a swelling of the large artery that carries blood from the heart to the body. get emergency medical help right away if you have sudden chest, stomach, or back pain. - intestine infection (pseudomembranous colitis). pseudomembranous colitis can happen with many antibacterial medicines, including ciprofloxacin tablets. call your healthcare provider right away if you get watery diarrhea, diarrhea that does not go away, or bloody stools. you may have stomach cramps and a fever. pseudomembranous colitis can happen 2 or more months after you have finished your antibacterial medicine. - serious heart rhythm changes (qt prolongation and torsade de pointes). tell your healthcare provider right away if you have a change in your heart beat (a fast or irregular heartbeat), or if you faint. ciprofloxacin tablets may cause a rare heart problem known as prolongation of the qt interval. this condition can cause an abnormal heartbeat and can be very dangerous. the chances of this event are higher in people: who are elderly with a family history of prolonged qt interval with low blood potassium (hypokalemia) who take certain medicines to control heart rhythm (antiarrhythmics) - who are elderly - with a family history of prolonged qt interval - with low blood potassium (hypokalemia) - who take certain medicines to control heart rhythm (antiarrhythmics) - joint problems. increased chance of problems with joints and tissues around joints in children under 18 years old can happen. tell your child's healthcare provider if your child has any joint problems during or after treatment with ciprofloxacin tablets. - sensitivity to sunlight (photosensitivity). see " what should i avoid while taking ciprofloxacin tablets?" - changes in blood sugar. people who take ciprofloxacin and other fluoroquinolone medicines with oral anti-diabetes medicines or with insulin can get low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia). follow your healthcare provider's instructions for how often to check your blood sugar. if you have diabetes and you get low blood sugar while taking ciprofloxacin tablets, stop taking ciprofloxacin tablets and call your healthcare provider right away. your antibiotic medicine may need to be changed. the most common side effects of ciprofloxacin tablets include: - nausea - diarrhea - changes in liver function tests - vomiting - rash tell your healthcare provider about any side effect that bothers you, or that does not go away. these are not all the possible side effects of ciprofloxacin tablets. for more information, ask your healthcare provider or pharmacist. call your doctor for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088 or drug ocean llc at 1-844-200-6566. how should i store ciprofloxacin tablets? - store at 20° to 25°c (68° to 77° f); excursions permitted to 15° to 30°c (59° to 86° f). keep ciprofloxacin tablets and all medicines out of the reach of children. general information about the safe & effective use of ciprofloxacin tablets. medicines are sometimes prescribed for purposes other than those listed in a medication guide. do not use ciprofloxacin tablets for a condition for which it is not prescribed. do not give ciprofloxacin tablets to other people, even if they have the same symptoms that you have. it may harm them. this medication guide summarizes the most important information about ciprofloxacin tablets. if you would like more information about ciprofloxacin tablets, talk with your healthcare provider. you can ask your healthcare provider or pharmacist for information about ciprofloxacin tablets that is written for healthcare professionals. what are the ingredients in ciprofloxacin tablets? - active ingredient: ciprofloxacin hydrochloride - inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch and titanium dioxide. this medication guide has been approved by the u.s. food and drug administration. trademarks are the property of their respective owner. rx only manufactured for: drug ocean llc, 1 bridge plaza, north central road, 6th floor, suite 675, fort lee, nj 07024 manufactured by: unique pharmaceutical laboratories (a div. of j. b. chemicals & pharmaceuticals ltd.), mumbai 400 030, india. revised: 10/2023

CIPROFLOXACIN HYDROCHLORIDE- ciprofloxacin hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

ciprofloxacin hydrochloride- ciprofloxacin hydrochloride tablet, film coated

remedyrepack inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride 500 mg

CIPROFLOXACIN HYDROCHLORIDE- ciprofloxacin hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

ciprofloxacin hydrochloride- ciprofloxacin hydrochloride tablet, film coated

remedyrepack inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) -